

Synthesis and Antimycobacterial Activity Evaluation of Isatin-derived 3-[(4-aryl-2-thiazolyl)]hydrazone]-1H-indol-2,3-diones

Leyla Yurttaş^{1,*}, Merve Ertaş², Meral Yılmaz Cankılıç³, Şeref Demirayak²

¹Anadolu University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, 26470, Eskişehir, Turkey

²Medipol University, School of Pharmacy, Department of Pharmaceutical Chemistry, 34810, İstanbul, Turkey

³Anadolu University, Faculty of Science, Department of Biology, 26470, Eskişehir, Turkey

ABSTRACT

A series of 3-[(4-aryl-2-thiazolyl)hydrazone]-1H-indol-2,3-dione derivatives (**2a-f**) were designed and synthesized using isatin as starting material. The obtained thiazole compounds were screened to investigate their antituberculosis activity against *Mycobacterium tuberculosis* H37RV (ATCC 27294). Among them, two compounds **2c** and **2d** were displayed antitubercular potential two-fold greater than standard drugs.

Keywords: Isatin, Indole, Thiazole, Antimycobacterial activity

INTRODUCTION

Tuberculosis (TB) is an airborne infectious disease persisting with high mortality which is caused by mycobacterium, *Mycobacterium tuberculosis*. Each year, over 12 million people suffer from the disease accompanied with 1.4 million death circumstances. Emergence of multidrug resistance against existing chemotherapeutic applications has led to find out a solution to this alarming increase of TB infections. Accordingly, Therefore, there is an intensive study to develop new, more effective antituberculous agents¹⁻⁵.

Indoles, especially 1H-indole-2,3-dione (isatin) are the most prevalent heterocyclic scaffolds which have a broad spectra of medical applications such as anti-HIV, antiviral, anti-tumor, antifungal, antiangiogenic, anti-convulsant, and antiparkinsonian activity⁶⁻⁸. In particular, antituberculous activity of various indole derivatives⁹⁻¹⁴ and isatin derivatives¹⁵⁻²² have attracted attention. The syn-

*Corresponding author: Leyla Yurttaş
E-mail address: lyurttas@anadolu.edu.tr

thetic feasibility and extensive use of this scaffold have led to medicinal chemists to this ring which has also stemmed from the interest in the biological and pharmacological properties^{23,24}.

In the other hand, thiazole ring is another important structure which have enhanced lipid solubility which is easily metabolized by routine biochemical reactions. Thiazole derivatives have well established with antituberculosis effects in many studies²⁵⁻³⁰. Studies combined these two rings, thiazole and isatin have also been reported^{31,32}.

In this work, based on isatin structure we have designed and synthesized new 3-[(4-aryl-2-thiazolyl)hydrazone]-1*H*-indol-2,3-dione derivatives. Six final compounds were screened for their antituberculosic activity, against *M. tuberculosis*. Log *P* values for the compounds were calculated, virtually and the biological results have been evaluated compared to standard drugs, isoniazid and rifampicin.

METHODOLOGY

Chemistry

Melting points were determined using a MP90 digital melting point apparatus (Mettler Toledo, OH) and were uncorrected. Spectroscopic data were recorded on the following instruments: a Bruker Tensor 27 IR spectrophotometer; a ¹H NMR (nuclear magnetic resonance) Bruker DPX- 300 FT-NMR spectrometer, ¹³C NMR, Bruker DPX 75 MHz spectrometer (Bruker Bioscience, Billerica, MA, USA); M+1 peaks were determined by Shimadzu LC/MS ITTOF system (Shimadzu, Tokyo, Japan).

Synthesis of 1*H*-Indole-2,3-dione-3-thiosemicarbazone (**1**)

0.02 mol of isatin, 0.02 mol of thiosemicarbazide and catalytic amount of acetic acid were refluxed in ethanol for 6 hours. After the end of the reaction was controlled by TLC, the reaction mixture was allowed to cool to room temperature and obtained precipitate was filtrated. The raw product was crystallised from ethanol.

Synthesis of 3-[(4-aryl-2-thiazolyl)hydrazone]-1*H*-indol-2,3-dione derivatives (**2a-f**)

3 mmol of gained intermediate (**1**) and appropriate α -bromoarylethanone derivative (3 mmol) were stirred in ethanol at room temperature. After the reaction was ended, the mixture was filtrated with excess ethanol and recrystallised from ethanol.

3-[[4-(2-Hydroxyphenyl)-2-thiazolyl]hydrazone]-1*H*-indol-2,3-dione (**2a**)

68 % yield; mp 310 °C. IR ν_{\max} (cm⁻¹): 3250 (NH), 3136 (OH), 1691 (C=O), 1616-1454 (C=C, C=N), 1386-981 (C-O, C-N). ¹H-NMR (300 MHz, DMSO-*d*₆, ppm) δ 6.84-6.97 (m, 3H, Ar-H), 7.09 (t, J=7.38 Hz, 1H, Ar-H), 7.17 (t, J=7.35 Hz,

1H, Ar-H), 7.34 (t, J=7.99 Hz, 1H, Ar-H), 7.53 (d, J=7.67 Hz, 1H, Ar-H), 7.68 (s, 1H, thiazole C₅-H), 7.92 (d, J=8.30 Hz, 1H, Ar-H), 10.54 (s, 1H, OH), 11.23 (s, 1H, NH), 13.53 (s, 1H, NH). ¹³C-NMR (75 MHz, DMSO-d₆, ppm) δ 109.00, 111.48, 116.95, 119.61, 119.95, 120.31, 121.78, 122.84, 128.51, 129.41, 130.95, 132.57, 141.79, 148.52, 155.48, 163.42, 165.68. HRMS (*m/z*): [M+H]⁺ calcd for C₁₇H₁₂N₄O₂S 337.37; found 337.08.

3-[[4-(3-Hydroxyphenyl)-2-thiazolyl]hydrazone]-1H-indol-2,3-dione (2b)

72 % yield; mp 316 °C. IR ν_{max} (cm⁻¹): 3161 (OH, NH), 1695 (C=O), 1616-1431 (C=C, C=N), 1346-987 (C-O, C-N). ¹H-NMR (300 MHz, DMSO-d₆, ppm) δ 6.71-6.74 (m, 1H, Ar-H), 6.97 (d, J=7.76 Hz, 1H, Ar-H), 7.09 (t, J=7.47 Hz, 1H, Ar-H), 7.21 (t, J=8.05 Hz, 2H, Ar-H), 7.31-7.37 (m, 2H, Ar-H), 7.53-7.54 (m, 2H, Ar-H and thiazole C₅-H), 9.48 (s, 1H, OH), 11.25 (s, 1H, NH), 13.35 (s, 1H, NH). ¹³C-NMR (75 MHz, DMSO-d₆, ppm) δ 107.13, 111.53, 113.09, 115.47, 116.96, 120.21, 120.32, 122.88, 130.16, 130.94, 132.48, 135.68, 141.74, 151.61, 158.11, 163.68, 166.25. HRMS (*m/z*): [M+H]⁺ calcd for C₁₇H₁₂N₄O₂S 337.37; found 337.07.

3-[[4-(4-Hydroxyphenyl)-2-thiazolyl]hydrazone]-1H-indol-2,3-dione (2c)

69 % yield; mp 285 °C. IR ν_{max} (cm⁻¹): 3165 (OH, NH), 1691 (C=O), 1612-1463 (C=C, C=N), 1327-987 (C-O, C-N). ¹H-NMR (300 MHz, DMSO-d₆, ppm) δ 6.79-6.86 (m, 3H, Ar-H), 6.96 (d, J=8.00 Hz, 1H, Ar-H), 7.08 (t, J=7.62 Hz, 1H, Ar-H), 7.34 (s, 1H, thiazole C₅-H), 7.53 (d, J=7.62 Hz, 1H, Ar-H), 7.71 (d, J=8.20 Hz, 2H, Ar-H), 9.60 (s, 1H, OH), 11.24 (s, 1H, NH), 13.32 (s, 1H, NH). ¹³C-NMR (75 MHz, DMSO-d₆, ppm) δ 104.21, 110.15, 111.51, 115.85, 116.02, 120.25, 121.73, 122.85, 125.81, 127.62, 130.85, 132.28, 141.68, 151.85, 157.87, 163.67, 166.19. HRMS (*m/z*): [M+H]⁺ calcd for C₁₇H₁₂N₄O₂S 337.37; found 337.07.

3-[[4-(2-Pyridyl)-2-thiazolyl]hydrazone]-1H-indol-2,3-dione (2d)

65 % yield; mp 298 °C. IR ν_{max} (cm⁻¹): 3124 (NH), 1683 (C=O), 1616-1464 (C=C, C=N), 1344-987 (C-O, C-N). ¹H-NMR (300 MHz, DMSO-d₆, ppm) δ 6.97 (d, J=8.80 Hz, 1H, Ar-H), 7.09 (t, J=7.54 Hz, 1H, Ar-H), 7.32-7.37 (m, 2H, Ar-H), 7.55 (d, J=7.96 Hz, 1H, Ar-H), 7.81 (s, 1H, thiazole C₅-H), 7.88 (t, J=7.96 Hz, 1H, Ar-H), 7.95-7.98 (m, 1H, Ar-H), 8.60 (d, J=4.28 Hz, 1H, Ar-H), 11.26 (s, 1H, NH), 13.36 (s, 1H, NH). ¹³C-NMR (75 MHz, DMSO-d₆, ppm) δ 111.02, 111.55, 120.17, 120.39, 120.54, 120.77, 122.91, 123.50, 131.04, 137.85, 141.82, 149.93, 152.10, 163.66, 166.90. HRMS (*m/z*): [M+H]⁺ calcd for C₁₆H₁₁N₅OS 322.36; found 322.07.

3-[[4-(3-Pyridyl)-2-thiazolyl]hydrazone]-1H-indol-2,3-dione (2e)

69 % yield; mp 318 °C. IR ν_{max} (cm⁻¹): 3298 (NH), 1666 (C=O), 1616-1462 (C=C, C=N), 1357-988 (C-O, C-N). ¹H-NMR (300 MHz, DMSO-d₆, ppm) δ 6.91 (d,

J=8.86 Hz, 1H, Ar-H), 7.06 (t, J=8.23 Hz, 1H, Ar-H), 7.31 (t, J=8.23 Hz, 1H, Ar-H), 7.48 (d, J=7.32 Hz, 1H, Ar-H), 7.90-7.95 (m, 1H, Ar-H), 8.04 (s, 1H, thiazole C₅-H), 8.75-8.79 (m, 2H, Ar-H), 9.25-9.26 (m, 1H, Ar-H), 11.25 (s, 1H, NH), 13.34 (s, 1H, NH). ¹³C-NMR (75 MHz, DMSO-*d*₆, ppm) δ 110.62, 111.56, 111.93, 119.97, 120.42, 120.25, 121.94, 122.89, 126.43, 126.86, 131.18, 132.44, 133.25, 139.82, 141.49, 141.91, 143.16, 143.31, 146.04, 163.57, 167.50. HRMS (*m/z*): [M+H]⁺ calcd for C₁₆H₁₁N₅OS 322.36; found 322.07.

3-[[4-(4-Pyridyl)-2-thiazolyl]hydrazono]-1H-indol-2,3-dione (2f)

67 % yield; mp 297 °C. IR ν_{max} (cm⁻¹): 3156 (NH), 1684 (C=O), 1620-1466 (C=C, C=N), 1346-985 (C-O, C-N). ¹H-NMR (300 MHz, DMSO-*d*₆, ppm) δ 6.91 (d, J=7.64 Hz, 1H, Ar-H), 7.05 (t, J=7.64 Hz, 1H, Ar-H), 7.30 (t, J=7.64 Hz, 1H, Ar-H), 7.48 (d, J=8.06 Hz, 1H, Ar-H), 7.76-7.80 (m, 2H, Ar-H), 7.92 (s, 1H, thiazole C₅-H), 8.58 (d, J=5.82 Hz, 2H, Ar-H), 11.23 (s, 1H, NH), 13.31 (s, 1H, NH). ¹³C-NMR (75 MHz, DMSO-*d*₆, ppm) δ 110.07, 110.40, 111.50, 111.57, 120.08, 120.15, 120.38, 121.81, 122.82, 126.36, 131.02, 131.26, 132.88, 141.07, 149.05, 150.55, 163.59, 166.99. HRMS (*m/z*): [M+H]⁺ calcd for C₁₆H₁₁N₅OS 322.36; found 322.07.

Microplate Alamar Blue Assay (MABA)


M. tuberculosis H37RV (ATCC 27294), was obtained from the American Type Culture Collection (ATCC). The microorganism was cultured at ATCC® Medium 1395: Middlebrook 7H9 broth with ADC enrichment at a temperature of 37°C for 10 day. The turbidity of the cultures was adjusted to McFarland standard no. 1. Rifampicin and isoniazid were used as standard drugs. Plates (Corning) were incubated at 37°C in 5% CO₂ for 7 days which were added freshly prepared 1:1 mixture of Alamar Blue reagent (1:10 dilution, Invitrogen, 156703SA) and 10% Tween 80 and then plates were reincubated at 37°C for 24h. After color change from blue to pink the reagent mixture was added to all the wells of the microplate. The results were expressed as MIC (at which all bacteria were inhibited)³³.

RESULTS AND DISCUSSION

Chemistry

Novel 3-[(4-aryl-2-thiazolyl)]hydrazono]-1H-indol-2,3-dione derivatives (**2a-f**) were synthesized in this study. Six compounds were obtained starting from isatin by nucleophilic addition and cyclization reactions in order, as can be seen **Scheme 1**. 1H-Indole-2,3-dione-3-thiosemicarbazone (**1**), the intermediate product was previously obtained molecule which was reported with a melting point of 240-241 °C in literature³⁴. The structures of the final compounds were elucidated with spectroscopic techniques. In the IR spectra of the compounds, characteristic bands at 3124-3298 cm⁻¹ and 1666-1695 cm⁻¹ were observed belong to N-H and C=O bonds, respectively. In the ¹H NMR spectra, thiazole C₅-H proton was detected at 7.34-8.04 ppm whereas cyclic amide (lactam) proton

of indole ring was determined at 11.23-11.26 ppm. All other peaks were seen at aromatic region and between ppm 6.71-9.26 ppm. In ^{13}C NMR spectra of the compounds, carbonyl carbon was resonated at about 165.68-167.50 ppm and other carbons were observed at 104.21-163.68 ppm. MS data was also confirmed molecular weights of the compounds.



Scheme 1: Synthesis of the compounds (**2a-f**). Reagents: (i) thiosemicarbazide, catalytic amount of acetic acid, ethanol, reflux, 6h; (ii) α -bromoarylethanone, ethanol, rt.

Antitubercular activity

The antimycobacterial activity of six final compounds (**2a-f**) were investigated against *Mycobacterium tuberculosis* H37RV (ATCC 27294) compared with standard drugs isoniazid and rifampin. Minimum inhibitor concentrations (MIC) of tested compounds were found in between 15.63-500 $\mu\text{g}/\text{mL}$ whereas MIC was calculated as 31.25 $\mu\text{g}/\text{mL}$ for standard drugs. Compounds **2c** with 4-hydroxyphenyl moiety and **2d** with 2-pyridyl moiety displayed significant activity which were determined as the most active compounds (MIC=15.63 $\mu\text{g}/\text{mL}$) even if higher than positive controls. Besides, compound **2e** showed half potential to standard drugs with MIC=62.50 $\mu\text{g}/\text{mL}$. The rest of the compounds did not exhibit remarkable antitubercular activity.

Mycobacterium tuberculosis is known with lipid wrapped cell wall which most of the antibiotics unable to penetrate³⁵. It is reported that the lipophilicity is closely associated with antimycobacterial potential of molecules³⁶. Log *P* values of the synthesized compounds were predicted using Molinspiration-Calculation of Molecular Properties and Bioactivity Score toolkit³⁷ and compared with activity results. When MIC values and lipophilic character of the compounds (calculated log *P*) were compared, there is no distinct relationship; however, molecules **2c** and **2d** possess the lowest MIC values with average log *P* values. Accordingly, it could be declared that 3-[(4-aryl-2-thiazolyl)hydrazono]-1*H*-indol-2,3-dione derivatives (**2a-f**) did not show correlative values between log *P* and antitubercular effects of the compounds.

Table 1: Antitubercular activities against *M. tuberculosis* H37RV (ATCC 27294) and log P predictions of compounds **2a-f**

Compounds	MIC ($\mu\text{g/mL}$)	Log P ^a
2a	250	2.89
2b	125	2.89
2c	15.63	2.92
2d	15.63	2.94
2e	62.50	3.52
2f	500	3.54
Isoniazid	31.25	-
Rifampin	31.25	-

^aCalculated by <http://www.molinspiration.com/>.

REFERENCES

- Shiradkar, M. R.; Kumar Murahari, K.; Gangadasu, H. R.; Suresh, T.; Kalyan, C. A.; Panchal, Kaur, D. R.; Burange, P.; Ghogare, J.; Mokale, V.; Raut, M. Synthesis of New S-derivatives of Clubbed Triazolyl Thiazole As Anti-*Mycobacterium tuberculosis* Agents. *Bioorg. Med. Chem.* **2007**, *15*, 3997-4008.
- Mjambili, F.; Njoroge, M.; Naran, K.; De Kock, C.; Smith, P. J.; Mizrahi, V.; Warner, D.; Chibale, K. Synthesis and Biological Evaluation of 2-Aminothiazole Derivatives as Antimycobacterial and Antiplasmodial Agents. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 560-564.
- Velezheva, V.; Brennan, P.; Ivanov, P.; Kornienko, A.; Lyubimov, S.; Kazarian, K.; Nikonenko, B.; Majorov, K.; Apt., A. Synthesis and Antituberculosis Activity of Indole-pyridine Derived Hydrazides, Hydrazide-hydrazones, and Thiosemicarbazones. *Bioorg. Med. Chem. Lett.* **2016**, *26*, 978-985.
- Shiradkar, M.; Bhandari, S. V.; Kale, R.; Laghate, A.; Rathi, A. Synthesis and Antimycobacterial Activity of Thiazole Derivatives. *Asian J. Chem.* **2006**, *18*, 2700-2704.
- Makam, P.; Kannan, T. 2-Aminothiazole Derivatives As Antimycobacterial Agents: Synthesis, Characterization, In Vitro and In Silico Studies. *Eur. J. Med. Chem.* **2014**, *87*, 643-656.
- Raj, R.; Gut, J.; Rosenthal, P. J.; Kumar, V. 1*H*-1,2,3-Triazole-tethered Isatin-7-chloroquinoline and 3-Hydroxy-indole-7-chloroquinoline Conjugates: Synthesis and Antimalarial Evaluation. *Biorg. Med. Chem.* **2014**, *24*, 756-759.
- Raja, S.; Prakash, C. R. Novel 1-(4-Substituted Benzylidene)-4-(1-(substituted methyl)-2,3-dioxindolin-5-yl)semicarbazide Derivatives for Use Against *Mycobacterium tuberculosis* H37Rv (ATCC 27294) and MDR-TB Strain. *Arch. Pharm. Res.* **2013**, *36*, 411-422.
- Haj Mohammad, K.; Tehrani, E.; Hashemi, M.; Hassan, M.; Kobarfard, F.; Mohebbi, S. Synthesis and Antibacterial Activity of Schiff Bases of 5-Substituted Isatins. *Chinese. Chem. Lett.* **2016**, *27*, 221-225.
- Zampieri, D.; Mamolo, M. G.; Laurini, E.; Scialino, G.; Banfi, E.; Vio, L. 2-Aryl-3-(1*H*-Azol-1-yl)-

1*H*-Indole Derivatives: A New Class of Antimycobacterial Compounds – Conventional Heating in Comparison with MW-Assisted Synthesis. *Arch. Pharm. Chem. Life Sci.* **2009**, *342*, 716–722.

10. Karthikeyan, S. V.; Perumal, S.; Shetty, K. A.; Yogeewari, P.; Sriram, D. A. Microwave-Assisted Facile Regioselective Fischer Indole Synthesis and Antitubercular Evaluation of Novel 2-Aryl-3,4-dihydro-2*H*-thieno[3,2-*b*]indoles. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 3006-3009.

11. Cihan-Üstündağ, G.; Çapan, G. Synthesis and Evaluation of Functionalized Indoles As Antimycobacterial and Anticancer Agents. *Mol. Divers.* **2012**, *16*, 525-539.

12. Karki, S. S.; Hazare, R.; Kumar, S.; Saxena, A.; Katiyar, A. Synthesis and Antimicrobial Activity of Some 3-Substituted-2-Oxindole Derivatives. *Turk. J. Pharm. Sci.* **2011**, *8*, 169-178.

13. Haj Mohammad, K.; Tehrani, E.; Mashayekhi, V.; Azerang, P.; Sardari, S.; Kobarfard, F.; Rostamizadeh, K. Synthesis and Antimycobacterial Activity of Novel Thiadiazolylhydrazones of 1-Substituted Indole-3-Carboxaldehydes. *Chem. Biol. Drug Des.* **2014**, *83*, 224-236.

14. Mashayekhi, V.; Haj Mohammad, K.; Tehrani, E.; Azerang, P.; Sardari, S.; Kobarfard, F. Synthesis, Antimycobacterial and Anticancer Activity of Novel Indole-Based Thiosemicarbazones. *Arch. Pharm. Res.* [Online early access]. DOI: 10.1007/s12272-013-0242-z. Published Online: September 24, **2013**.

15. Saundane, A. R.; Walmik, P. Synthesis, Antioxidant, Antimicrobial, Antimycobacterial, and Cytotoxic Activities of Azetidinone and Thiazolidinone Moieties Linked to Indole Nucleus. *J. Chem.* **2013**, 1-9.

16. Sriram, D.; Alexandra Aubry, Perumal Yogeewaria and L. M. Fisher Gatifloxacin derivatives: Synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 2982-2985.

17. Feng, L. S.; Liu, M. L.; Shuo, W.; Yun, C.; Hao, X. Q.; Meng, S.; Guo, H. Y. Synthesis and In Vitro Antimycobacterial Activity of Balofloxacin Ethylene Isatin Derivatives. *Eur. J. Med. Chem.* **2010**, *45*, 3407-3412.

18. Feng, L. S.; Liu, M. L.; Shuo, W.; Yun, C.; Su-jie, L.; Hui-yuan, G. Synthesis and In Vitro Antimycobacterial Activity of Moxifloxacin Methylene and Ethylene Isatin Derivatives. *Chem. Res. Chinese U.* **2012**, *28*, 61-66.

19. Feng, L. S.; Liu, M. L.; Zhang, S.; Chai, Y.; Wang, B.; Zhang, Y. B.; Lv, K.; Guan, Y.; Guo, H. Y.; Xiao, C. L. Synthesis and In Vitro Antimycobacterial Activity of 8-OCH₃ Ciprofloxacin Methylene and Ethylene Isatin Derivatives. *Eur. J. Med. Chem.* **2011**, *46*, 341-348.

20. Pandeya, S. N.; Smitha, S.; Jyoti, M.; Sridhar, S. K. Biological Activities of Isatin and Its Derivatives. *Acta Pharm.* **2005**, *55*, 27-46.

21. Aboul-Fadl, T.; Bin-Jubair, F. A. S. Anti-Tubercular Activity of Isatin Derivatives. *Int. J. Res. Pharm. Sci.* **2010**, *1*, 113-126.

22. Jeankumar, V. U.; Alokam, R.; Sridevi, J. P.; Suryadevara, P.; Matikonda, S. S.; Peddi, S.; Sahithi, S.; Alvala, M.; Yogeewari, P.; Sriram, D. Discovery and Structure Optimization of a Series of Isatin Derivatives as *Mycobacterium tuberculosis* Chorismate Mutase Inhibitors. *Chem. Biol. Drug Des.* **2014**, *83*, 498-506.

23. Kumar, R. S.; Rajesh, S. M.; Perumal, S.; Banerjee, D.; Yogeewari, P.; Sriram, D. Novel Three-component Domino Reactions of Ketones, Isatin and Amino acids: Synthesis and Discovery of Antimycobacterial Activity of Highly Functionalized Novel Dispiropyrrrolidines. *Eur. J. Med. Chem.* **2010**, *45*, 411-422.

24. Meenakshi, K.; Gopal, N.; Sarangapani, M. Synthesis, Characterization and Antimicrobial Activity of Some Novel Schiff and Mannich Bases of Isatin. *Int. J. Pharm. Pharmaceut. Sci.* **2014**, *6*, 318-322.
25. Rangaraju, A.; Pannerselvam, P.; Murali, K. Synthesis of Novel 1*H*-Indole-2,3-dione Derivatives as Potent Antimycobacterial Agents. *Int. J. Adv. Pharm. Biol.Chem.* **2013**, *2*, 616-622.
26. Mundhe, D.; Chandewar, A. V.; Shiradkar, M. R. Design and Synthesis of Substituted Clubbed Triazolyl thiazole as XDR & MDR Antituberculosis Agents Part-II. *Pharm. Chem.* **2011**, *3*, 89-102.
27. Nagesh, H. N.; Suresh, A.; Sri Sairam, S. D. S.; Sriram, D.; Yogeewari, P.; Chandra Sekhar, K. W. S. Design, Synthesis and Antimycobacterial Evaluation of 1-(4-(2-Substitutedthiazol-4-yl)phenethyl)-4-(3-(4-substitutedpiperazin-1-yl)alkyl)piperazine Hybrid Analogues. *Eur. J. Med. Chem.* **2014**, *84*, 605-613.
28. Mamolo, M. G.; Falagiani, V.; Zampieri, D.; Vio, L.; Banfi, E.; Scialino, G. Synthesis and Antimycobacterial Activity of (3,4-Diaryl-3*H*-thiazol-2-ylidene)-hydrazide Derivatives. *Il Farmaco* **2003**, *58*, 631-637.
29. Aridoss, G.; Amirthaganesan, S.; Kim, M. S.; Kim, J. T.; Jeong, Y. T. Synthesis, Spectral and Biological Evaluation of Some New Thiazolidinones and Thiazoles Based on t-3-Alkyl-r-2,c-6-Diarylpiperidin-4-ones. *Eur. J. Med. Chem.* **2009**, *44*, 4199-4210.
30. Makam, P.; Kankanala, R.; Prakash, A.; Kannan, T. 2-(2-Hydrazinyl)thiazole derivatives: Design, Synthesis and In Vitro Antimycobacterial studies. *Eur. J. Med. Chem.* **2013**, *69*, 564-576.
31. Ramshid, P. K.; Jagadeeshan, S.; Krishnan, A.; Mathew, M.; Nair, S. A.; Pillai, M. R. Synthesis and In Vitro Evaluation of Some Isatin-Thiazolidinone Hybrid Analogues as Anti-Proliferative Agents. *Med. Chem.* **2010**, *6*, 306-312.
32. Meleddu, R.; Distinto, S.; Corona, A.; Bianco, G.; Cannas, V.; Esposito, F.; Artese, A.; Alcaro, S.; Matyus, P.; Bogdan, D.; Cottiglia, F.; Tramontano, E.; Maccioni, E. (3*Z*)-3-(2-[4-(aryl)-1,3-Thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1*H*-indol-2-one Derivatives As Dual Inhibitors of HIV-1 Reverse Transcriptase. *Eur. J. Med. Chem.* **2015**, *93*, 452-460.
33. Kumar, M.; Khan, I. A.; Verma, V.; Qazi, G. N. Microplate Nitrate Reductase Assay Versus Alamar Blue Assay For MIC Determination of *Mycobacterium tuberculosis*. *Int. J. Tuberc. Lung Dis.* **2005**, *9*, 939-941.
34. Singh, A. S.; Shukla, S. K.; Ahamad, I.; Quraishi, M. A. Solvent-Free Microwave-Assisted Synthesis of 1*H*-Indole-2,3-dione Derivatives. *J. Heterocyclic Chem.* **2009**, *46*, 571-574.
35. Brennan, P. J.; Nikaido, H. The Envelope of Mycobacteria. *Ann. Rev. Biochem.* **1995**, *64*, 29-63.
36. Krátký, M.; Vinsová, J.; Novotná, E.; Mandíková, J.; Wsól, V.; Trejtnar, F.; Ulmann, V.; Stolaríková, J.; Fernandes, S.; Bhat, S.; Liu, J. O. Salicylanilide Derivatives Block *Mycobacterium tuberculosis* is Through Inhibition of Isocitrate Lyase and Methionine Aminopeptidase. *Tuberculosis*, **2012**, *92*, 434-439.
37. <http://www.molinspiration.com/cgi-bin/properties>. (Last Accessed: 26.08.20106).

(Received 25 August 2016; accepted 15 November 2016)

We start each day to heal more lives.

**HEALING LIVES.
HEALING THE FUTURE.
THAT'S WHAT WE DO.**



ABDIIBRAHIM

BRAIN AND SPINAL CORD TUMORS

Cooperation between specialists of tumor council and intelligent technology



Our organization has been accredited as an Academic Medical Center Hospital by JCI.



MEDIPOL
CALL
CENTER

+

444 70 44



MEDIPOL
MEGA
MEDIPOL
MEGA
HOSPITAL
COMPLEX



facebook.com/medipolsaglik



twitter.com/medipolsaglik



youtube.com/MedipolSaglikGrubu